期刊文献+

缺血性脑卒中患者血浆脂蛋白(a)与血小板凝集率、纤维蛋白原和D-二聚体间的关系研究 被引量:1

The correlation between lipoprotein (a) with D-Dimer, fibrinogen and platelet aggregate test in ischemic cerebral patients
下载PDF
导出
摘要 目的 研究急性缺血性脑卒中患者脂蛋白(a)[lipoprotein(a),Lp(a)]、血小板凝集率(Platelet Aggregate Test,Pag T)、纤维蛋白原(Fibrinogen,Fbg)和D-二聚体(D-Dimer)的变化原因以及它们之间的关系.方法 测定66例缺血性脑卒中患者及106例对照组血浆中的Lp(a)、PagT、Fbg和D-Dimer的水平.结果 缺血性脑卒中患者血浆中Lp(a)、PagT和D-Dimer水平明显高于对照组水平(P<0.05=,而Fbg水平两组间差异无显著性意义(P>0.05);Lp(a)、PagT和D-Dimer是脑卒中的危险因素,与脑卒中关系的密切程度D-Dimer〉PagT〉Lp(a);Lp(a)与PagT和D-Dimer呈正相关关系(P<0.05=.结论 缺血性脑卒中患者血浆中Lp(a)水平增高,高水平的Lp(a)可能通过促进凝血系统反应和抑制纤溶系统反应导致患者急性缺血性脑卒中的发生. Objective To explore the causes and relation ship between lipoprotein (a) [Lp (a)]with D-Dimer, fibrinogen (Fbg) and platelet aggregate test (PagT) in ischemic cerebral patients. Methods Lp (a), PagT, Fbg and D-Dimer level in 66 cases of ischemic cerebrum and 106 cases healthy control group were detected by the turbidity method. Results Lp (a), PagT and D-Dimer level obviously higher in ischemic cerebral patients than those of healthy control group (P〈 0.05), while the difference in the level of Fbg is not significant (P 〉 0.05). Lp (a), PagT and D-Dimer are considered as risk factors to ischemic cerebral patients, and the risk degree is D-Dimer〉PagT〉Lp(a). Lp (a) is positive correlation with PagT and D-Dimer in ischemic cerebral patients (P〈 0.05). Conclusion Lp (a) level is increased in ischemic cerebral patients. Lp (a) may promote blood coagulation reaction and inhibit fibrinolysis system response, thus result in acute ischemic cerebral happening.
作者 林秀瑾
出处 《中国急救复苏与灾害医学杂志》 2011年第10期864-866,共3页 China Journal of Emergency Resuscitation and Disaster Medicine
关键词 缺血性脑卒中 脂蛋白(a) 血小板凝集率 纤维蛋白原 D-二聚体 Ischemic Cerebral Patients Lipoprotein (a) Platelet Aggregate Test Fibrinogen D-Dimer
  • 相关文献

参考文献8

二级参考文献36

  • 1辛夷,肖伟忠,张勇.脑梗死患者血清TNF-α和IL-8检测的临床意义[J].兰州医学院学报,2004,30(2):25-26. 被引量:5
  • 2李征,龚浠平,李尧,王拥军.急性脑梗死各亚型患者的血脂水平分析[J].神经疾病与精神卫生,2004,4(5):340-342. 被引量:8
  • 3各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33004
  • 4Koenig W.Fibrinogen in cardiovascular disease:an update[J].Thromb Haemost,2003,89(4):601-609. 被引量:1
  • 5Shai I,Rimm E B,Hankinson S E,et al.Lipoprotein(a) and coronary heart disease among women:beyond a cholesterol carrier[J].Eur Heart J,2005,26(16):1633-1639. 被引量:1
  • 6Lominadze D,Dean W L,Tyagi S C,et al.Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease[J].Acta Physiol,2010,198(1):1-13. 被引量:1
  • 7Eriksson A C,Jonasson L,Lindahl T L,et al.Static platelet adhesion,flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease:a randomised cross-over study[J].J Transl Med,2009,7:42. 被引量:1
  • 8Bennet A,Angelantonio E,Erqou S,et al.Lipoprotein(a) levels and risk of future coronary heart disease:large-scale prospective data[J].Arch Intern Med,2008,24,168(6):598-608. 被引量:1
  • 9Zlatohlávek L,Zídková K,Vrablík M,et al.Lipoprotein(a) and its position among other risk factors of atherosclerosis[J].Physiol Res,2008,57(5):777-783. 被引量:1
  • 10Danik J S,Paré G,Chasman D I,et al.Novel loci,including those related to Crohn disease,psoriasis,and inflammation,identified in a genome-wide association study of fibrinogen in 17 686 women:the Women′s Genome Health Study[J].Circ Cardiovasc Genet,2009,2(2):134-41. 被引量:1

共引文献39

同被引文献15

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部